Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life ...

Catalent (NYSE:CTLT) rose 1.6% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings could close as soon as Monday. The US Federal Trade Commission doesn't ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024. Catalent's ...

Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.